Combination of vasostatin gene therapy with cyclophosphamide inhibits growth of B16[F10] melanoma tumours

• Autorzy: Jazowiecka-Rakus J. , Jarosz M. , Szala S.
• Języki publikacji: EN

Abstrakty

EN

Angiogenesis, i.e. formation of new blood vessels out of pre-existing capillaries, is essential to the development of tumour vasculature. The discovery of specific antiangiogenic inhibitors has important therapeutic implications for the development of novel cancer treatments. Vasostatin, the N-terminal domain of calreticulin, is a potent endogenous inhibitor of angiogenesis and tumour growth. In our study, using B16(F10) murine melanoma model and electroporation we attempted intramuscular transfer of human vasostatin gene. The gene therapy was combined with antiangiogenic drug dosing schedule of a known chemotherapeutic (cyclophosphamide). The combination of vasostatin gene therapy and cyclophosphamide administration improved therapeutic effects in melanoma tumours. We observed both significant inhibition of tumour growth and extended survival of treated mice. To our knowledge, this is one of the first reports showing antitumour efficacy of electroporation-mediated vasostatin gene therapy combined with antiangiogenic chemotherapy.

Słowa kluczowe

EN

gene therapy; cyclophosphamide; combination; melanoma tumour; angiogenesis; vasostatin

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2006
• Tom: 53
• Numer: 1
• Opis fizyczny: p.199-202,fig.,ref.

Twórcy

autor

Jazowiecka-Rakus J.

autor

Jarosz M.

autor

Szala S.

Bibliografia

• Blezinger P, Wang J, Gondo M, Quezada A, Mehrens D, French M, Singhal A, Sullivan S, Rolland A, Ralston R, Min W (1999) Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol 17: 343–348.
• Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O’Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60: 1878–1886.
• Burke PA, DeNardo SJ (2001) Antiangiogenic agents and their promising potential in combined therapy. Crit Rev Oncol Hematol 39: 155–171.
• Cao Y (1999) Therapeutic potentials of angiostatin in the treatment of cancer. Haematologica 84: 643–650.
• Chen CT, Lin J, Li Q, Phipps SS, Jakubczak JL, Stewart DA, Skripchenko Y, Forry-Schaudies S, Wood J, Schnell C, Hallenbeck PL (2000) Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin. Hum Gene Ther 11: 1983–1996.
• Chen QR, Kumar D, Stass SA, Mixson AJ (1999) Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res 59: 3308–3312.
• Cichon T, Jamrozy L, Glogowska J, Missol-Kolka E, Szala S (2002) Electrotransfer of gene encoding endostatin into normal and neoplastic mouse tissues: inhibition of primary tumor growth and metastatic spread. Cancer Gene Ther 9: 771–777.
• Eskens F (2004) Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer 12: 1–7.
• Folkman J (2003) Angiogenesis and apoptosis. Semin Cancer Biol 13: 159–167.
• Gething MJ, Sambrook J (1989) Protein folding and intracellular transport: studies on influenza virus haemagglutinin. Biochem Soc Symp 55: 155–166.
• Gollins H, McMahon J, Wells KE, Wells DJ (2003) High-efficiency plasmid gene transfer into dystrophic muscle. Gene Ther 10: 504–512.
• Hartikka J, Sawdey M, Cornefert-Jensen F, Margalith M, Barnhart K, Nolasco M, Vahlsing HL, Meek J, Marquet M, Hobart P, Norman J, Manthorpe M (1996) An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum Gene Ther 7: 1205–1217.
• Madison EL, Bird P (1992) A vector, pSHT, for the expression and secretion of protein domains in mammalian cells. Gene 121: 179–180.
• O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277–285.
• Pike SE, Yao L, Jones KD, Cherney B, Appella E, Sakaguchi K, Nakhasi H, Teruya-Feldstein J, Wirth P, Gupta G, Tosato G (1998) Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 188: 2349–2356.
• Pike SE, Yao L, Setsuda J, Jones KD, Cherney B, Appella E, Sakaguchi K, Nakhasi H, Atreya CD, Teruya-Feldstein J, Wirth P, Gupta G, Tosato G (1999) Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood 94: 2461–2468.
• Prox D, Becker C, Pirie-Shepherd SR, Celik I, Folkman J, Kisker O (2003) Treatment of human pancreatic cancer in mice with angiogenic inhibitors. World J Surg 27: 405–411.
• Xiao F, Wei Y, Yang L, Zhao X, Tian L, Ding Z, Yuan S, Lou Y, Liu F, Wen Y, Li J, Deng H, Kang B, Mao Y, Lei S, He Q, Su J, Lu Y, Niu T, Hou J, Huang MJ (2002) A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Ther 9: 1207–1213.
• Yao L, Pike SE, Setsuda J, Parekh J, Gupta G, Raffeld M, Jaffe ES, Tosato G (2000) Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood 96: 1900–1905.
• Yao L, Pike SE, Pittaluga S, Cherney B, Gupta G, Jaffe ES, Tosato G (2002a) Anti-tumor activities of the angiogenesis inhibitors interferon-inducible protein-10 and the calreticulin fragment vasostatin. Cancer Immunol Immunother 5: 358–366.
• Yao L, Pike SE, Tosato G (2002b) Laminin binding to the calreticulin fragment vasostatin regulates endothelial cell function. J Leukoc Biol 71: 47–53.
• Ziche M, Donnini S, Morbidelli L (2004) Development of new drugs in angiogenesis. Curr Drug Targets 5: 485–493.